/IMA
IMA Stock - ImageneBio Inc
Healthcare|BiotechnologyNASDAQ
$6.18-0.16%
$0.01 (-0.16%) • Dec 19
30
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-73.0%upside
Target: $1.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IMA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.12 – $6.24
TARGET (TP)$1.67
STOP LOSS$5.69
RISK/REWARD1:-9.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.44
52W High$23.28
52W Low$6.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.50M | $9.16M | $15.62M | $30.98M | $9.19M |
| Gross Profit | $3.50M | $8.14M | $-48,703,000 | $-16,123,000 | $-35,653,000 |
| Gross Margin | 100.0% | 88.9% | -311.8% | -52.0% | -387.8% |
| Operating Income | $-37,000,000 | $-75,417,000 | $-70,904,000 | $-34,138,000 | $-44,519,000 |
| Net Income | $-36,568,000 | $-68,166,000 | $-68,765,000 | $-34,115,000 | $-44,256,000 |
| Net Margin | -1044.8% | -744.2% | -440.3% | -110.1% | -481.4% |
| EPS | $-1.02 | $-1.63 | $-1.90 | $-0.95 | $-3.16 |
Company Overview
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
0%
Sell / Underperform
1
50%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$16
Average Target
↑ 158.9% Upside
Now
$2
Low
$16
Average
$30
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | Wedbush | Resumed | Underperform | $2 |
| October 24th 2025 | Leerink Partners | Initiation | Outperform | $30 |
Earnings History & Surprises
IMABeat Rate
68%
Last 19 quarters
Avg Surprise
-4.2%
EPS vs Estimate
Beats / Misses
13/5
1 met exactly
Latest EPS
$-2.91
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.41vs$-0.41
Q2 24
+30.0%
$-0.28vs$-0.40
Q3 24
+12.9%
$-0.27vs$-0.31
Q4 24
+29.6%
$-0.19vs$-0.27
Q1 25
+5.3%
$-0.18vs$-0.19
Q2 25
+14.3%
$-0.18vs$-0.21
Q3 25
+57.1%
$-0.06vs$-0.14
Q4 25
-98.0%
$-2.91vs$-1.47
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 5, 2026 | $-1.45 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.47 | $-2.91 | -98.0% | ✗ MISS |
Q3 2025 | Jul 24, 2025 | $-0.14 | $-0.06 | +57.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.27 | $-0.19 | +29.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.40 | $-0.28 | +30.0% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.41 | $-0.41 | 0.0% | = MET |
Q4 2023 | Nov 9, 2023 | $-0.44 | $-0.40 | +9.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.48 | $-0.44 | +8.3% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.46 | $-0.39 | +15.2% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-0.53 | $-0.39 | +26.4% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.50 | $-0.48 | +4.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.48 | $-0.57 | -18.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.42 | $-0.47 | -11.9% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.51 | $0.07 | +113.7% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-0.68 | $-2.52 | -270.6% | ✗ MISS |
Latest News
Wedbush Assumes ImageneBio at Underperform, Announces Price Target of $2
📉 NegativeBenzinga•Nov 25, 2025, 02:03 PM
ImageneBio Announces It Intends To Submit Protocol Amendment For Phase 2b ADAPTIVE Study To Expand Number, Exposure Range Of Dosing Regiments, Optimize Feasibility Of Study
➖ NeutralBenzinga•Nov 12, 2025, 12:18 PM
ImageneBio Q3 EPS $(2.91) Misses $(1.28) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 12:17 PM
ImageneBio On Oct 23, Elects Not To Renew Agreement With Miragene; Extends Term For Miragene Services By Six Months; Total Fees For Miragene Extension Services Are $200K
➖ NeutralBenzinga•Oct 29, 2025, 12:07 PM
ImageneBio CFO Jotin Marango Resigns Effective October 20, 2025
📉 NegativeBenzinga•Oct 10, 2025, 08:49 PM
Frequently Asked Questions about IMA
What is IMA's current stock price?
ImageneBio Inc (IMA) is currently trading at $6.18 per share. The stock has moved -0.16% today.
What is the analyst price target for IMA?
The average analyst price target for IMA is $1.67, based on 1 analyst.
What sector is ImageneBio Inc in?
ImageneBio Inc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IMA's market cap?
ImageneBio Inc has a market capitalization of $0.07 billion, making it a small-cap company.
Does IMA pay dividends?
No, ImageneBio Inc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
CNTX
Context Therapeutics Inc.
$1.27
Mkt Cap: $0.1B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
OVID
Ovid Therapeutics Inc.
$1.47
Mkt Cap: $0.1B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
Explore stocks similar to IMA for comparison